Pharmaceutical Medicine

, Volume 22, Issue 2, pp 127–129 | Cite as


  • 1. Call for Greater Global Dissemination of Clinical Science

  • 2. Investment in Genetic Research Pays Off

  • 3. Reviving Serendipity in Drug Discovery a “Utopian Fantasy”?

  • 4. Pharma Industry Less than Healthy

  • 5. MACE an Unreliable Endpoint in Cardiovascular Studies

  • 6. Ethics of Clinical Trials called into Question

  • 7. Mandatory Trial Results Disclosure has Implications for Journals

  • 8. UK Yellow Card Scheme: Pharmacists to Encourage Patient Reporting

1. Call for Greater Global Dissemination of Clinical Science

“There is more need for clinical science of international interest to be globally disseminated”, conclude researchers from Greece and the US.

The researchers evaluated data concerning the country of origin of studies published in 11 leading medical journals over a period of 35 years.

The Lancetdemonstrated the most diversity regarding the origin of published studies; between 1971 and 1975, 62.6% of studies published in this journal were from the UK, whereas between 2001 and 2005 only...


Clozapine Major Adverse Cardiac Event Bare Metal Stents Major Adverse Cardiac Event Rate Yellow Card Scheme 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



  1. Falagas ME, Alexiou VG. An analysis of trends in globalisation of origin of research published in major general medical journals. Int J Clin Pract 2008 Jan; 62 (1): 71–5PubMedCrossRefGoogle Scholar


  1. Hackam DG, Hackam AS. Translation of genetic discoveries into clinical therapies. Ann Intern Med 2008 Feb 3; 148 (3): 246–7PubMedGoogle Scholar


  1. Klein DF. The loss of serendipity in psychopharmacology. JAMA 2008 Mar 5; 299 (9): 1063–5PubMedCrossRefGoogle Scholar


  1. Jack A. Balancing big pharma’s books. BMJ 2008 Feb 23; 336 (7641): 418–9PubMedCrossRefGoogle Scholar


  1. Kip KE, Hollabaugh K, Marroquin OC, et al. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol 2008 Feb 19; 51 (7): 701–7PubMedCrossRefGoogle Scholar


  1. O’Neil P. Ethics guidelines for clinical trials to be revised. CMAJ 2008 Jan 15; 178 (2): 138PubMedCrossRefGoogle Scholar


  1. Groves T. Mandatory disclosure of trial results for drugs and devices: new US law will require public posting of all the main results and data on harms. BMJ 2008 Jan 26; 336 (7637): 170PubMedCrossRefGoogle Scholar


  1. MHRA. Members of the public to be encouraged by pharmacists to report suspected side effects of medicines. Media Release: 18 Feb 2008 [online]. Available from URL: Google Scholar

Copyright information

© Adis Data Information BV 2008

Personalised recommendations